GARDEN CITY, N.Y. and REHOVOT, Israel, Oct. 18, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTCQB: AITB), a
clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of
patients with respiratory conditions including serious lung infections and pulmonary hypertension, today presented a poster with
data on high-dose in vitro inhaled NO at the North American Cystic Fibrosis Conference, being held October 18-20 in Denver, CO.
The poster, entitled: “High-Dose Inhaled Nitric Oxide as a Potential Therapy Against Mycobacterial Abscessus
Infection in Cystic Fibrosis,” demonstrated the activity of high-dose NO against various multidrug-resistant clinical isolates
of M. abscessus in vitro. Several multidrug-resistant clinical isolates of M. abscessus showed significant
susceptibility to 250 ppm NO treatment. Even though the high-dose NO kill rate was not uniform across all M.
abscessus strains, none of the clinical isolates were resistant to NO monotherapy. Future studies are being planned to assess
NO activity in combination with commonly used antibiotics for NTM lung infection.
The poster can be accessed on the company website at www.AIT-PHARM.com.
“MABSC is a devastating and debilitating disease with no currently approved therapy. We are pleased to present
data that show NO treatment as a potential meaningful therapy in these patients,” said Steven Lisi, Chairman and Chief Executive
Officer of AIT Therapeutics. “We look forward to showing further in vitro data in the near future in combination with antibiotics
commonly used to treat NTM as we believe we can identify an optimal combination treatment.”
About Nitric Oxide (NO)
Nitric Oxide (NO) is a powerful molecule proven to play a critical role in a broad array of biological
functions. In the airways, NO is believed to play a key role in the innate immune system at concentrations of approximately
200 ppm. In vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, both
gram-positive and gram-negative, but also against other diverse organisms including mycobacteria, fungi, yeast and parasites, and
has the potential to eliminate multi-drug resistant strains.
About Mycobacterium abscessus complex (MABSC) of the Lungs
MABSC is the most aggressive and difficult to treat species of nontuberculous mycobacteria (NTM). There are currently no approved
treatments for MABSC. Current standard-of-care is a cocktail of antibiotics that often proves to be ineffective with severe adverse
effects. Most patients suffering from MABSC have an underlying disease, such as cystic fibrosis or chronic obstructive
pulmonary disease (COPD). The median survival of those suffering from MABSC is less than 5 years.
About AIT Therapeutics Inc.
AIT Therapeutics Inc. is a clinical-stage medical device and biopharmaceutical company using nitric oxide (NO) to treat respiratory
and other diseases. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that
are not effectively addressed with current standards of care, as well as pulmonary hypertension, in various settings. AIT is
currently advancing its revolutionary NO Generator and Delivery System in clinical trials for the treatment of bronchiolitis and
severe lung infections such as nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.
Forward-Looking Statement
This press release contains “forward-looking statements.” Forward-looking statements include statements about our
expectations, beliefs, or intentions regarding our product offerings, business, financial condition, results of operations,
strategies or prospects. You can identify such forward-looking statements by the words “expects,” “intends,” “plans,” “projects,”
“believes,” “estimates,” “likely,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or
conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not
relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events,
activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet
occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ
materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are
only predictions and reflect our views as of the date they are made with respect to future events and financial performance. Many
factors could cause our actual activities or results to differ materially from the activities and results anticipated in
forward-looking statements, including risks related to: our approach to discover and develop novel drugs, which is unproven and may
never lead to marketable products; our ability to fund and the results of further pre-clinical and clinical trials; obtaining,
maintaining and protecting intellectual property utilized by our products; our ability to enforce our patents against infringers
and to defend our patent portfolio against challenges from third parties; our ability to obtain additional funding to support our
business activities; our dependence on third parties for development, manufacture, marketing, sales, and distribution of products;
the successful development of our product candidates, all of which are in early stages of development; obtaining regulatory
approval for products; competition from others using technology similar to ours and others developing products for similar uses;
our dependence on collaborators; and our short operating history. We undertake no obligation to update, and we do not have a policy
of updating or revising, these forward-looking statements, except as required by applicable law.
CONTACT
Steven Lisi, Chief Executive Officer
AIT Therapeutics, Inc.
Steve@AIT-Pharm.com
Bob Yedid
LifeSci Advisors, LLC
Bob@LifeSciAdvisors.com
(646) 597-6989
